NIDO-361
DrugTablets containing 100mg of NIDO-361 for oral administration.
NCT Number: NCT06411912
The purpose of this study is to evaluate the safety, tolerability, and efficacy of NIDO-361 in adult patients with Spinal and Bulbar Muscular Atrophy (SBMA).
Looking for future studies?
Notify Me18 year–70 year
Male
Interventional
Phase 2
Rigshospitalet, Klinik for Nerve- og Muskelsygdomme & Copenhagen Neuromuscular Center, Copenhagen, Denmark
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Tablets containing 100mg of NIDO-361 for oral administration.
Placebo oral tablets
Time frame: Baseline, Day 180, Days 360-374 (Last Visit)
Analysis of thigh included adductors, hamstrings, and quadriceps and total (whole-body) included muscles in the rotator cuff, arm, torso, and leg muscle regions (38 muscles in total). Muscles were categorized according to their fat content as follows: A-muscles were defined as muscle fat fraction (MFF) < 50% and muscle fat infiltration (MFI) < 10%. A-muscles have a low or slightly elevated fat content to a level that can be present in individuals without a neuromuscular disease. B-muscles were defined as MFF < 50% and MFI ≥ 10%. B-muscles have a muscle fat content at a level where disease involvement is likely. C-muscles were defined as MFF ≥ 50%. C-muscles have a muscle fat content where more than 50% of the muscle tissue has been replaced by fat and most of the functional capacity is likely lost.
Time frame: Through study completion, an average of 1 year
Adverse events were coded with MedDRA Dictionary Version 26.1.
Time frame: Through study completion, an average of 1 year
Time frame: Through study completion, an average of 1 year
Adverse events were coded with MedDRA Dictionary Version 26.1.
Time frame: Baseline, Day 180, Day 360
The modified Spinal and Bulbar Muscular Atrophy Functional Rating Scale (m-SBMAFRS) is calculated as the sum of the items for the truncal and lower-limb domains from the SBMAFRS, which is a validated functional rating scale developed from the Amyotrophic Lateral Sclerosis Functional Rating Scale. Each item has five responses options scoring 0 (worst) to 4 (normal). A higher score indicates better functioning. Total range is 0 (worst) to 30 (normal).
Time frame: Baseline, Day 180, Day 360
2-minute walk test (2MWT) measures the distance traveled (meters) in 2 minutes.
Time frame: Baseline, Day 180, Day 360
6-minute walk test (6MWT) measures the distance traveled (meters) in 6 minutes.
Time frame: Baseline, Day 180, Day 360
The Timed Up and Go Test (TUG) is used to assess mobility and to provide an estimate on balance and risk of falling. Patients are asked to rise from a chair, walk 3 meters, turn around, return to the chair, and sit. The time that it takes to complete the task is recorded. Assistive devices, orthoses, and ankle braces are allowed.
Time frame: Baseline, Treatment (Days 331 to 360)
The Actigraph device is a non-invasive research-grade accelerometer based wearable device that was used to objectively measure free-living physical activity. The data from these devices was used to assess and detect changes in physical activity intensity, upper arm movements, and walking patterns.
Time frame: Baseline, Treatment (Days 331 to 360)
The Actigraph device is a non-invasive research-grade accelerometer based wearable device that was used to objectively measure free-living physical activity. The data from these devices was used to assess and detect changes in physical activity intensity, upper arm movements, and walking patterns.
Time frame: Baseline, Treatment (Days 331 to 360)
The Actigraph device is a non-invasive research-grade accelerometer based wearable device that was used to objectively measure free-living physical activity. The data from these devices was used to assess and detect changes in physical activity intensity, upper arm movements, and walking patterns.
Time frame: Baseline, Treatment (Days 331 to 360)
The Actigraph device is a non-invasive research-grade accelerometer based wearable device that was used to objectively measure free-living physical activity. The data from these devices was used to assess and detect changes in physical activity intensity, upper arm movements, and walking patterns.
Time frame: Baseline, Treatment (Days 331 to 360)
The Actigraph device is a non-invasive research-grade accelerometer based wearable device that was used to objectively measure free-living physical activity. The data from these devices was used to assess and detect changes in physical activity intensity, upper arm movements, and walking patterns.
Time frame: Baseline, Day 180, Day 360
Grip strength (lbs) is averaged across three trials for the right and left hands separately using a handheld dynamometer (HHD).
Nido Biosciences, Inc.
Industry
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of NIDO-361 in Patients With Spinal and Bulbar Muscular Atrophy (SBMA)
Acronym: PIONEER KD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05517603
Bulbo-Spinal Atrophy, X-Linked, Central Nervous System Diseases
Orange, California, United States
View Trial DetailsNCT00303446
Bulbo-Spinal Atrophy, X-Linked, Central Nervous System Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT03555578
Bulbo-Spinal Atrophy, X-Linked, Central Nervous System Diseases
Tokyo, Japan
View Trial DetailsNCT02024932
Bulbo-Spinal Atrophy, X-Linked, Central Nervous System Diseases
Orange, California, United States
View Trial Details